Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib Extension in wAIHA
NCT04138927Phase 3Enrolling by invitation
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Oct 2019
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of fostamatinib in warm antibody autoimmune hemolytic anemia (WAIHA), sponsored by Rigel Pharmaceuticals, Inc.. Started Oct 2019; status: enrolling by invitation.
02
Drugs
fostamatinib
03
Conditions
warm antibody autoimmune hemolytic anemia (WAIHA)
Beyond the preview
Go deeper on NCT04138927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138927.